Independent report

Medicines adaptive pathways for patients

Looks at issues relating to the ethics of medicines adaptive pathways for patients (MAPPs) including the use of real world data.



Medicines adaptive pathways for patients (MAPPs) is an innovative, more adaptive approach to medicines development being discussed and piloted by the European Medicines Agency.

This report, which explores the views of patients and professionals, focusses on the MAPPs process but its findings could be applicable to similar early access schemes. It has therefore formed part of the evidence to inform the Accelerated Access Review.

The report, by the Centre for the Advancement of Sustainable Medical Innovation, was commissioned by the Department of Health and Office for Life Sciences.

Published 22 March 2016